Publications by authors named "Natasha E Woodward"
Background: Adjuvant aromatase inhibitors (AI) improve survival compared to tamoxifen in postmenopausal women with hormone receptor-positive stage I to III breast cancer. In approximately half of these women, AI are associated with aromatase inhibitor-induced musculoskeletal symptoms (AIMSS), often described as symmetrical pain and soreness in the joints, musculoskeletal pain and joint stiffness. AIMSS may have significant and prolonged impact on women's quality of life.
View Article and Find Full Text PDFArticle Synopsis
- Talazoparib is a PARP inhibitor that targets breast cancer cells with BRCA1 or BRCA2 mutations, showing effectiveness in a Phase III study (EMBRACA) compared to physician's choice of chemotherapy.
- The study involved 431 patients, with results indicating that those receiving talazoparib experienced longer progression-free survival, higher objective response rates, and overall better patient-reported outcomes compared to those on traditional chemotherapy.
- Common side effects were similar across groups, with talazoparib users experiencing anemia and fatigue, while a small percentage had grade I and II alopecia, but overall, talazoparib showed significant clinical advantages in patients with g-mutated advanced breast cancer.
Background: Survival for stage I to III, hormone receptor-positive, breast cancer has substantially improved over time due to advances in screening, surgery and adjuvant therapy. However many adjuvant therapies have significant treatment-related toxicities, which worsen quality of life for breast cancer survivors. Postmenopausal women with hormone receptor-positive breast cancer are now prescribed aromatase inhibitors (AI) as standard, with longer durations of therapy, up to 10 years, being considered for certain women.
View Article and Find Full Text PDF